The short version
- Demant, the Danish company behind Oticon, says hearing-aid revenue grew 17% in the third quarter, well above its own expectations.
- It credits the August launch of the Oticon Reveal in the US and now expects 7 to 8% growth across the company for 2026.
- The growth is measured in money, not in units, and US commercial unit sales were flat in the quarter before.
Demant, the Danish group that owns Oticon, Bernafon and HearingLife, said on October 9 that preliminary third-quarter figures showed 17% organic growth in its hearing-aid business and 11% for the group as a whole. It raised its 2026 forecast for organic growth to 7 to 8%, from 6 to 7%, and its operating profit range to DKK 4.7 to 5.0 billion. The full report is due November 3.
The company credits a “very strong” launch of the Oticon Reveal, which reached the US commercial market in August, along with January’s Oticon Zeal. Chief executive Søren Nielsen said the reception had let the hearing-aid business “grow well above our expectations.” HearingTracker, which covered the results this week, describes Reveal as using AI to handle speech and surrounding sound.
Demant also now expects the global hearing-aid market to grow 4 to 5% by value this year, up from 3 to 4%.
Those are revenue figures. They say people are paying for new devices, and not that more people with hearing loss are getting help. HearingTracker notes that US commercial unit sales were flat in the second quarter, with private-pay growth offset by declines in managed care.
